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Abstract
Angiogenesis, the formation of new blood vessels from preexisting blood vessels, is a process that supports
tumor growth and metastatic dissemination. Lymphangiogenesis also facilitates metastasis by increasing dis-
semination through the lymphatic vessels (LVs). Even after treatment with antiangiogenic agents, breast cancer
patients are vulnerable to LV-mediated metastasis. We report that a 14–amino acid peptide derived from trans-
membrane protein 45A shows multimodal inhibition of lymphangiogenesis and angiogenesis in breast cancer.
The peptide blocks lymphangiogenic and angiogenic phenotypes of lymphatic and blood endothelial cells induced
by tumor-conditioned media prepared from MDA-MB-231 breast cancer cells. The peptide delays growth of MDA-
MB-231 tumor xenografts and normalizes tumor-conditioned lymph nodes (LNs). These studies demonstrate the
antilymphangiogenic and antiangiogenic potential of the peptide against primary tumors and premetastatic, tumor-
conditioned regional LNs. Mechanistically, the peptide blocks vascular endothelial growth factor receptors 2 and 3
(VEGFR2/3) and downstream proteins by binding to neuropilin 1/2 (NRP1/2) and inhibiting VEGFR2/3 and NRP1/2
complex formation in the presence of VEGFA/C.
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Introduction
Angiogenesis is a process that tumors employ to promote their growth
and spread [1]. Although blood vessels contribute to cancer cell dis-
semination, tumor metastasis is significantly facilitated by the lym-
phatic system as well [2]. Studies in micrometastases of melanoma,
gastric cancer, and breast cancer have shown that 16% to 20% of
cancer patients showed lymphatic invasion, whereas 3% to 5.4%
showed blood vessel invasion, bypassing the lymphatic system [3–5].
Lymphatic vessels (LVs) offer several advantages over blood vessels
for cancer cell dissemination. The LVs have a discontinuous basement
membrane that facilitates intravasation and extravasation of cancer cells.
The LVs have a much slower flow rate of lymphatic fluid with lower
shear stress, resulting in less tumor cell death, and a higher lymphatic
concentration of hyaluronic acid, a molecule with potent cancer cell–
protecting properties [6].
Metastasis is significantly enhanced by an increase in lymphangio-
genesis in primary tumors and regional lymph nodes (LNs): These
Abbreviations: BVD, blood vessel density; FAK, focal adhesion kinase; HSP27, heat
shock protein 27; HUVECs, human umbilical vein endothelial cells; LECs, lymphatic
endothelial cells; LN, lymph node; LVD, lymphatic vessel density; MECs, microvascular
endothelial cells; NRP, neuropilin; RTCA, real-time cell analysis; SFM, serum-free
media; TCM, tumor-conditioned media; VEGFR, vascular endothelial growth factor
receptor; VEGF, vascular endothelial growth factor
Address all correspondence to: Dr Aleksander S. Popel, Department of Biomedical
Engineering, Johns Hopkins University School of Medicine, 611 Traylor Research
Building, 720 Rutland Avenue, Baltimore, MD 21205. E-mail: apopel@jhu.edu
1This work was supported by the National Institutes of Health (grant R01 CA138264)
and the Safeway Foundation for Breast Cancer. The authors declare that they have no
competing interests. A.S.P. is a co-founder and serves as the Chief Scientific Officer of
AsclepiX Therapeutics, LLC; the terms of this arrangement are being managed by the
Johns Hopkins University in accordance with its conflict of interest policies.
2This article refers to supplementary materials, which are designated by Figures W1 to
W8 and are available online at www.neoplasia.com.
Received 2 October 2012; Revised 11 December 2012; Accepted 11 December 2012
Copyright © 2013 Neoplasia Press, Inc. All rights reserved 1522-8002/13/$25.00
DOI 10.1593/neo.121638
www.neoplasia.com
Volume 15 Number 2 February 2013 pp. 112–124 112
pathologic phenomena at the two different sites are referred to as
tumor lymphangiogenesis and LN lymphangiogenesis [7]. In terms
of tumor lymphangiogenesis, peritumoral or intratumoral LVs play a
role as initial routes of cancer cell dissemination from the primary
tumor to the lymphatic system. LN lymphangiogenesis is also central
for lymphatic metastasis; as shown, premetastatic or postmetastatic
LNs feature highly enhanced lymphangiogenesis [8]. Before invasion,
primary tumors overexpress lymphangiogenic factors and deliver
these factors to tumor-draining LNs through LVs, thus inducing
neolymphangiogenesis in the LNs [9]. Additionally, the LN lymph-
angiogenesis is maintained and further enhanced after cancer cells
metastasize to the LNs [10]. These suggest that tumor lymphangio-
genesis and LN lymphangiogenesis would be crucial targets of anti-
metastatic agents.
Breast cancer is the most commonly diagnosed female malignancy
in the United States [11]. Though antiangiogenic or hormonal ther-
apies combined with other agents are in development to treat breast
cancer [12], many patients with metastatic breast cancer (e.g., triple-
negative breast cancer subtypes) have suffered from recurrence of sec-
ondary tumors in regional LNs and distant organs [13,14]. Avastin
(bevacizumab), a vascular endothelial growth factor A (VEGFA)
monoclonal antibody, was revoked by the Food and Drug Adminis-
tration from clinical indications for advanced breast cancer, because
it had not improved overall survival rates of metastatic breast cancer
patients [15]. This limitation of Avastin can be interpreted on the
basis of the evidence that antiangiogenic therapies result in a hypoxic
condition in tumors, overexpression of lymphangiogenic factors,
enhancing tumor metastasis through the lymphatics [16,17]. Thus,
lymphatic metastasis is an alternative way of tumor resistance to
current antiangiogenic therapies.
Previously, our bioinformatics approach using peptides known to
have antiangiogenic activity as the input resulted in the identification
of more than 100 novel antiangiogenic endogenous peptides in the
human proteome. These peptides are parts of larger proteins of dif-
ferent classes, including type IV collagen, thrombospondin-1, CXC
chemokines, serpins, and somatotropins [18]. We recently discovered
that small peptides from somatotropin domain–containing proteins
are antilymphangiogenic and antiangiogenic in cell-based experiments
[19]. On the basis of these findings, here we investigate the in vivo
activity of one of the most potent somatotropin peptides, derived
from a transmembrane protein 45A that we denote SP5031 (amino
acid sequence: LLRSSLILLQGSWF-NH2) in breast cancer models,
including primary tumor xenografts and tumor-conditioned regional
LNs, and investigate its mechanisms of action.
Materials and Methods
Peptide Synthesis and Handling
Peptides were produced by Bachem (Torrance, CA) by using a
solid-phase synthesis technique. High-performance liquid chroma-
tography (HPLC) and mass spectrometry (MS) analyses of the pep-
tides were provided by the manufacturer to indicate a purity of more
than 95%. In preparation of peptide stock solution, DMSO was used
as a solvent at a maximum concentration of 5% (vol/vol) in distilled
water. We verified that all experiments were carried out with <0.3%
concentrations of DMSO so as not to harm cells. Theoretical iso-
electric points of the peptides were calculated, using the Compute
pI/Mw online software in ExPASy provided by the Swiss Institute
of Bioinformatics (Lausanne, Switzerland).
Cell Culture
Lymphatic endothelial cells (LECs), microvascular endothelial
cells (MECs), and human umbilical vein endothelial cells (HUVECs)
were purchased from Lonza (Walkersville, MD). LECs and MECs
were propagated in microvascular endothelial cell growth medium-2
(EGM-2MV; Lonza). HUVECs was propagated in endothelial cell
growth medium-2 (EGM-2, Lonza). MDA-MB-231 triple-negative
human breast cancer cells andMCF-7 estrogen receptor–positive human
breast cancer cells were supplied by Dr Zaver Bhujwalla (Departments
of Radiology and Oncology, Johns Hopkins Medical Institutions) and
propagated in RPMI 1640 medium (Gibco, Carlsbad, CA) sup-
plemented with 10% FBS (Gibco) and 1% penicillin-streptomycin
(Gibco). Cells were maintained under standard conditions of 37°C
and 5% CO2 and the passage numbers of endothelial cells were kept
between 3 and 6.
Preparation and Characterization of
Tumor-Conditioned Media
MDA-MB-231 cells in complete growth media (RPMI 1640)
were plated onto 175-mm2 tissue culture plates. When the cell number
reached 10 × 106 (confluent monolayer), the complete media were
removed, and the cells were carefully rinsed with serum-free media
(SFM; RPMI 1640 without supplements), and then, 5 ml of SFM
was added. After 24 hours of incubation at 37°C, tumor-conditioned
media (TCM) were carefully gathered, centrifuged, and filtered
through 0.2-μm sterile syringe filters (Corning, Tewksbury, MA) to
remove cells. The TCM was stored in aliquots at −80°C to avoid
multiple freeze-thaws.
A Proteome Profiler Antibody Arrays Kit for Human Angiogenesis
(R&D Systems,Minneapolis, MN) was used to determine angiogenesis-
related factors in TCM. Array membranes were blocked with 2 ml of
blocking buffer provided in the kit for 1 hour at room temperature on a
rocking platform. One thousand microliters of TCM was mixed with
500 μl of dilution buffer provided in the kit. The prepared sample was
added to the blocked membrane and the membrane was incubated
overnight at 4°C. After three rinses with washing buffer provided in
the kit, 1.5 ml of HRP-conjugated detection antibody in the kit was
added for signal detection.
Migration and Adhesion Assays
Cell migration and adhesion assays were performed using Real-
Time Cell Analysis (RTCA) System (ACEA Biosciences, San Diego,
CA), as described previously [19]. To evaluate cell migration, we used
Cell Invasion and Migration plates (CIM-plates; Roche, Indianapolis,
IN) and an RTCA System. The membrane of the top chamber of a
CIM-plate was precoated with 20 μg/ml fibronectin (Sigma-Aldrich,
St Louis, MO). One hundred eighty microliters of TCM was added
to the bottom chamber as a chemoattractant. Cells (45,000 HUVECs;
120,000 LECs/well) were added to the top chamber with or without
peptides. After stabilizing CIM-plates for 30 minutes at room tem-
perature, the chamber was loaded in the RTCA machine, and the
cell indices were measured continuously for 24 hours. Cell indices at
20 hours were selected for analysis. For adhesion assays, 100 μl of 2×
concentrated peptide solution was added to the appropriate wells of an
E-plate (Roche). LECs and HUVECs (25,000 cells/well) in TCMwere
added next to each well, diluting peptides to the appropriate final
concentration. After equilibrating at room temperature for 30 minutes,
the E-plate was loaded into the RTCA System. Cell indices at 3 hours
were analyzed.
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Tube Formation Assay
Fifty microliters of Matrigel (BD Biosciences, Bedford, MA) was
loaded in each well of a 96-well plate, and the plate was incubated at
37°C for 30 minutes. One hundred microliters of LECs and HUVECs
in TCM with or without peptides were added on top of the matrix in
the 96-well plate (15,000 cells/well). The plate was then incubated at
37°C, and the wells were imaged using a Nikon microscope at 20 hours
(Nikon Instruments Inc, Melville, NY). Quantification of tube forma-
tion was assisted by S.CORE, a web-based image analysis system (S.CO
Life Science, Munich, Germany). Tube formation indices represent
the degree of tube formation. The indices were calculated using the
equation below. The values of the variables used in the equation below
were obtained automatically by S.CORE.
ðTube formation indexÞ
= ðmean single tube indexÞ2 × ð1 − conf luent areaÞ
× ðnumber of branching points = total length skeletonÞ:
Cell Proliferation Assay
Cell proliferation assay was carried out by using cell proliferation
reagent WST-1 (Roche), as described previously [19]. For the prolif-
eration assay, 2000 cells were plated onto a 96-well plate and allowed
to attach for 4 hours, and the media were replaced with media with
peptides. After 72 hours at 37°C, the number of viable cells was mea-
sured after adding WST-1, a reagent that is converted to a formazan
whose absorbance at 450 nm is measured in a plate reader.
Oris Cell Migration Assay
Motility of MDA-MB-231 and MCF-7 cells was assessed by using
the Oris Pro Cell Migration Assay Kit with fibronectin precoated
plates (Platypus Technology, Madison, WI). Fifty thousand cancer
cells in complete media (RPMI 1640, 10% FBS) were added to each
well (100 μl/well) of the 96-well plate containing stoppers to prevent
the cells from settling in the center region of the wells. Cells were
allowed to adhere for 8 hours, after which the stoppers were carefully
removed. After one rinse with SFM, 100 μl of complete media (10%
or 25% FBS) with or without the peptide was added. After 18 hours,
the cells were labeled with CellTracker Green (Invitrogen, Carlsbad,
CA), according to the manufacturer’s protocol. The cells that migrated
to the center of the well were quantified by reading fluorescence at
485/530 nm on a Victor V plate reader (PerkinElmer, Salem, MA)
and imaged using a fluorescence microscope (Eclipse T-100; Nikon,
Brighton, MI). A detection mask was applied to the bottom of the
plate to observe only the cells that migrated into the previously
restricted region by obstructing the other parts of the well.
MCF-7 Cell Adhesion Assay
MCF-7 cells were prelabeled with CellTracker Green (Invitrogen)
according to the manufacturer’s protocol. While cells were being
labeled, a 96-well plate was coated with 20 μg/ml fibronectin for
30 minutes at 37°C. Labeled cells in 25% FBS complete media were
plated at a density of 10,000 cells/well in the 96-well plate with or
without SP5031. After 3 hours, cells were washed three times with
Dulbecco phosphate-buffered saline (DPBS) (with Ca2+, Mg2+) after
which the fluorescence intensity was measured using the Victor V
plate reader. For the negative control, cell adhesion after 0 hour of
cell/peptide treatment was observed.
In Vivo MDA-MB-231 Xenograft Models
Animal protocols were approved by the Institutional Care and Use
Committee at the Johns Hopkins Medical Institutions. MDA-MB-
231 cells (2 × 106) were orthotopically inoculated into the lower tho-
racic mammary fat pad of severe combined immunodeficient mice
under anesthesia [50 mg/kg ketamine + 5 mg/kg acepromazine in
phosphate-buffered saline (PBS)], and the tumors were allowed to
grow until they reached around 100 mm3. Peptide solution in PBS
(15 mg/kg) or PBS (vehicle) was injected intraperitoneally (i.p.) and
continued for 27 days. The tumor size was measured and the volume
was calculated as previously described [20], using the formula: V =
0.52 × a × b2, where a is the long axis and b is the short axis of the
tumor. Each group has 8 to 10 mice.
In Vivo Tumor-Conditioned Regional LN Models
Fifty microliters of MDA-MB-231 TCM or SFM was subcuta-
neously administered through the scruff of athymic nude mice.
These animals were either treated with SP5031 or with the vehicle
(PBS; i.p. administration, 15 mg/kg) for 14 days. After 14 days,
animals were killed; the axillary and brachial LNs were excised and
the LN volumes were measured. The LN volumes (V ) were calculated
according to the formula: V = 0.52 × a × b2, where a is the long axis
and b is the short axis of the LN. The LNs were rinsed in PBS and
fixed in 4% formalin for 16 hours for immunohistochemistry. Each
group has four mice, giving 16 regional LNs (eight axillary LNs +
eight brachial LNs) per experimental group.
Matrigel Plug Assay
Growth factor reduced Matrigel (High Concentration; BD Bio-
sciences) containing rh-VEGF165 (380 ng/ml; R&D Systems), recombi-
nant human fibroblast growth factor-basic (rh-bFGF) (380 ng/ml; R&D
Systems), and heparin (10 IU/plug; Sigma-Aldrich) was mixed with or
without the peptide (200 μg/ml) in a total volume of 400 μl. The
Matrigel mixtures were subcutaneously injected on both flanks on the
abdominal side of athymic nude mice under anesthesia. After 10 days,
the gels were removed, imaged, and analyzed by immunohistochemistry.
Immunohistochemistry
Axillary and brachial LNs fixed in 4% formalin were placed in
30% sucrose solution in PBS, incubated overnight at 4°C, and frozen
in the Tissue-Tek Optimal Cutting Temperature compound (Sakura,
Tokyo, Japan). Serial sections of 10-μm thickness were cut parallel to
the long axis of the LN at −20°C. After blocking with 5% normal
chicken serum in PBST (5% chicken serum, 0.1% cold fish gelatin,
0.1% Triton X-100, 0.05% Tween 20, and 0.05% sodium azide in
PBS) for 1 hour at room temperature, the sections were treated with
rat monoclonal anti-mouseMECA-79 antibody (Santa Cruz Biotechnol-
ogy, Inc, Santa Cruz, CA) overnight at 4°C. After three rinses with
PBST, sections were incubated with Alexa Fluor 647 chicken anti-rat
IgG in the dark (Invitrogen) for 1 hour at room temperature. After
three rinses, the second blocking agent (5% normal donkey serum
in PBST) was added and incubation at room temperature in the
dark was continued for another hour. Goat polyclonal anti-mouse
LYVE-1 antibody was added and incubation was continued overnight
after switching to 4°C, and Alexa Fluor 488 donkey anti-goat IgG
(Invitrogen) was added and processed as above. The samples were
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mounted with the ProLong Gold anti-fade reagent (Invitrogen).
Matrigel plugs and breast tumor tissues were fixed in 4% formalin
fixative solution for 16 hours and sent to a commercial vendor (Covance
Inc, Princeton, NJ) to probe with CD34 and LYVE-1 antibodies,
assessing blood vessels and LVs. We quantified MECA-79, CD34, and
LYVE-1 using the FRiDA software ( JohnsHopkinsUniversity, Baltimore,
MD) and ImageJ (National Institutes of Health, Bethesda, MD), mea-
suring the pixel intensity/4× frame of randomly selected 12 images in
each group. Images shown are magnified to ×10 or ×20 to visually show
greater surface area, and the fluorescent images from the LNs were
merged, using the ImageJ software.
Histopathology
We performed hematoxylin and eosin (H&E) staining on lungs,
liver, spleen, and kidney of animals that are treated with vehicle
(PBS) or SP5031 for 27 days, assessing peptide toxicity in the animals.
Lungs, liver, spleen, and kidney were harvested, rinsed with DPBS,
and fixed in 4% formalin for 16 hours at room temperature. The
organs were placed in 30% sucrose solution in DPBS, incubated over-
night at 4°C, and frozen in the Tissue-Tek Optimal Cutting Temper-
ature compound. Sections of 10-μm thickness were cut at −20°C. The
sections were rehydrated in PBS for 5 minutes (×3) and immersed in
the filtered 0.1% Mayer’s hematoxylin solution (Sigma-Aldrich) for
10 minutes. Then, the slides were rinsed with tap water for 5 minutes.
Next, the stained sections were co-stained with eosin by immersing
the slides in 0.5% eosin Y solution (Sigma-Aldrich) for 1 minute.
The slides were dipped in distilled water 10 times (×10). The sections
were dehydrated in ascending ethanol (EtOH) solutions: 50% EtOH ×
10 dips, 70% EtOH × 10 dips, 30-second incubation in 95%
EtOH, and 1-minute incubation in 100% EtOH. The slides were
rinsed with xylene two times. The slide was mounted with mounting
media (50% glycerin) and covered with a slide glass. The slides were
observed by using Olympus BX51TF with DP70 color camera
(Olympus, Center Valley, PA).
Phospho–Receptor Tyrosine Kinase Proteome Analysis
A Proteome Profiler Antibody Arrays Kit for human phospho–
receptor tyrosine kinase (p-RTK; R&D Systems) was used to deter-
mine which of the RTKs that are phosphorylated in the presence of
TCM phosphorylation were inhibited by SP5031. Briefly, 2 × 106
LECs treated with or without 50 μM SP5031 for 90 minutes were
stimulated by TCM (3× concentrated) for 10 minutes at 37°C. To
prepare the concentrated TCM (3×), we used 3.6 ml of RPMI SFM
and 20 × 106 cancer cells in plates: Other conditions were the same
as the protocol for preparation of TCM described above. Treatments
were stopped by adding cold PBS; the cells were lysed in cold lysis
buffer [150 mM NaCl, 1 mM EDTA, 100 μl/ml protease inhibitors
(Sigma-Aldrich), 10 μl/ml phosphatase inhibitors (Sigma, St Louis,
MO), and 1% Triton X-100] for 2 hours at 4°C and then scraped
to collect the lysates. Cell lysates were spun at 14,000g for 15 min-
utes to remove cell debris. Array membranes were blocked with
blocking buffer provided in the kit. Cell lysate was mixed with dilu-
tion buffer, the prepared sample was added to the blocked membrane,
and the membrane was incubated overnight at 4°C. After three rinses,
anti–phospho-tyrosine-HRP detection antibody (diluted by 1:2000
with dilution buffer in the kit) was added, and the antibody-bound
streptavidin-HRP complex was detected by using a chemilumines-
cence detection reagent (GE Healthcare, United Kingdom).
Western Blot Assay
HUVECs, MECs, and LECs were grown in complete growth media
and plated onto tissue culture–treated six-well plates at 400,000 cells/
well in complete media (CM). Cells were starved in SFM for 24 hours
after which SP5031 was added for 90 minutes. VEGFA (20 ng/ml) or
VEGFC (100 ng/ml) was added, and the incubation was continued for
10 minutes at 37°C. Treatments were stopped by adding cold PBS, and
cell lysates were prepared as described above. Cell lysates were separated
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to nitrocellulose blots (Invitrogen). We blocked
for 1 hour with 5%nonfat milk + 1%BSA in tris-buffered saline and tween
20 (TBST) and probed with antibodies of interest including phos-
phorylated VEGF receptor 2 (VEGFR2; Y1175), VEGFR2, phospho-
mitogen-associated protein kinase kinase 3/6 (pMKK3/6; S189/S207),
phospho-p38 mitogen-associated protein kinase (pp38MAPK; T180/
Y182), MAP kinase-activated protein kinase 2 (p-MAPKAPK2;
T334), phosphorylated heat shock protein 27 (HSP27; S82), phospho-
Src (pSrc; Y416), Src, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; Cell Signaling Technology, Inc, Danvers, MA), and
4G10 pan-tyrosine phosphorylation antibody (Santa Cruz Biotechnol-
ogy, Inc). GAPDH was used as a loading control. Secondary antibodies
were added at 1:2000 dilution and protein bands detected with a
chemiluminescence detection reagent (GE Healthcare).
Sulfo-SBED Cross-Linking Assay
We used a cross-linking strategy with Sulfo-SBED cross-linking re-
agent to identify target receptors of SP5031 on blood endothelial cells
(BECs) and LECs. A Sulfo-SBED Biotin Label Transfer Reagent
(Thermo Scientific Inc, Rockford, IL) has three functional groups, in-
cluding an amine-reactive N-hydroxysuccinimide (NHS)-ester group, a
UV-activatable aryl azide group, and a biotin group. The peptide was
reacted with Sulfo-SBED at ratio of 1:3 in PBS at room temperature
for 2 hours, in the dark. After the reaction, unreacted Sulfo-SBED was
quenched with excess Tris-HCl. HUVECs or LECs were rapidly
gathered from cell culture plates, using a nonenzymatic cell dissocia-
tion reagent (Sigma-Aldrich) and rinsed with PBS to remove serum pro-
teins on the cell surface. Probe-conjugated peptide (15 μM; 30 μl) was
added to 1 × 107 HUVECs or LECs in 1 ml of PBS in a 24-well
plate, and the mixture was incubated at room temperature for 1 hour
on a rocker. The 24-well plate was exposed in UV (365 nm) without
a lid for 15 minutes. UV-exposed cells were rinsed with 1 ml of cold
PBS twice (centrifuged at 3000 rpm, 4°C for 5 minutes) to remove
unreacted probes and dead cells. The rinsed cells were resuspended in
500 μl of cell lysis buffer and incubated in an ice bath for 1 hour, with
vortexing every 20 minutes. Fifteen microliters of streptavidin sepharose
bead (Cell Signaling Technology, Inc) was added in the cell lysates, and
the mixture was incubated at 4°C for 2 hours. The beads were rinsed
three times with 500 μl of lysis buffer. The beads were collected by a brief
spin in a microfuge tube. The collected beads were boiled for 10minutes
with sample reducing buffer (4×). The reduced sample was centrifuged at
14,000g for 15 minutes, and the supernatant was separated by SDS-
PAGE and probed with anti-biotin, anti–neuropilin 1 (NRP1), anti-
NRP2, anti-CD44, anti-VEGFR2, and anti-VEGFR3 (Cell Signaling
Technology, Inc). For competition assays, we added 10× molar excess
of unlabeled SP5031 or 10× unlabeled SP5002 in the wells containing
LECs/BECs and the SP5031 probe. After the same cross-linking pro-
cess as above, LEC or BEC cell lysates were immunoprecipitated with
anti-NRP1 or anti-NRP2 (Cell Signaling Technology, Inc) antibodies
plus Protein A/G Plus Agarose (Santa Cruz Biotechnology, Inc) as
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above; the immunoprecipitated proteins were separated and probed
with anti-biotin (HRP-linked) antibodies.
Co-immunoprecipitation
Co-immunoprecipitation (co-IP) was performed to investigate
molecular interaction between NRP1 and VEGFR2 in HUVECs or
between NRP2 and VEGFR3 in LECs. To optimize conditions for
co-IP, we tested cell lysis buffers with different ionic strengths and
detergents (50, 100, and 150 mM NaCl; 0.1% and 1% Triton X-100)
in VEGFA-induced VEGFR2-NRP1 complex formation in HUVEC
lysates. To determine SP5031 activity, we treated 4 × 106 HUVECs
or 1.2 × 107 LECs with SP5031 for 90 minutes followed by induction
with VEGFA (40 ng/ml) or VEGFC (100 ng/ml). Optimized cell lysis
buffer [50 mMNaCl, 20 mM Tris-HCl, 1 mM EDTA, 100 μl/ml pro-
tease inhibitors (Sigma), 10 μl/ml phosphatase inhibitors (Sigma), and
1% Triton X-100 (Sigma)] was used to conserve the receptor complex.
Five hundred microliters of cell lysates was incubated overnight at
4°C with antibodies suitable for IP: rabbit anti-VEGFR2 antibody;
rabbit anti-NRP1 antibody; rabbit anti-NRP2 antibody (Cell Signaling
Technology, Inc); mouse anti-VEGFR3 (EMD Millipore, Billerica,
MA). Protein A/G Plus Agarose (Santa Cruz Biotechnology, Inc) was
added and the tubes rocked for 3 hours at 4°C. The beads were rinsed
three times with 500 μl of cell lysis buffer, and the protein complex was
reduced and separated by SDS-PAGE and probed with the following
antibodies: mouse anti-NRP1, mouse anti-VEGFR2 (R&D Systems),
mouse anti-NRP2, rabbit anti-NRP2, rabbit anti-VEGFR3 (Cell Sig-
naling Technology, Inc), and mouse anti-VEGFR3 (EMD Millipore).
Statistical Analysis
Error bars correspond to SEM, unless otherwise stated. Differences
between a control and a peptide-treated group are regarded as signif-
icant when P is less than .05 using the Student’s t test.
Results
SP5031 Blocks Migration, Adhesion, and Tube Formation of
LECs and BECs in TCM
The RTCA System was used to measure TCM-induced migration
and adhesion of LECs and BECs with or without SP5031. SP5031
peptide significantly inhibited TCM-induced migration of LECs and
BECs. TCM contains multiple angiogenesis-related factors as will be
presented below. SP5031 (50 μM) inhibited LEC migration by
83.5% (P < .01) and BECmigration by 56.0% from control (Figure 1,
B and C ). SP5031 also inhibited LEC adhesion (30.0% inhibition
Figure 1. In vitro activity ofSP5031onLECsandBECs. (A) Amino acid sequenceof theSP5031peptide. (B) Percent LECmigration at 20hours.
**P< .01 versus TCM-treated control. (C) Percent BECmigration (*P< .05). (D) Percent LEC adhesion (*P< .05). (E) Percent BEC adhesion
(*P < .05). (F) SP5031 inhibits TCM-induced LEC tube formation. LEC tube index (S.CORE quantification) shows dose response of SP5031
(*P< .05 and **P< .01). S.CORE (S.CO Life Science) is a web-based image analysis system [19]. Scale bars represent 200 μm. (G) BEC tube
formation (*P < .05). Scale bars represent 200 μm.
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with 10 μM SP5031; 61.0% inhibition with 50 μM SP5031) and
BEC adhesion (17.2% inhibition with 10 μM SP5031; 42.4% inhib-
ition with 50 μM SP5031; Figure 1, D and E ). The original data for
LEC/BEC migration and adhesion are shown in Figure W1. SP5031
limited TCM-induced LEC tube formation (33.5% inhibition with
10 μM SP5031; 93.0% inhibition with 50 μM SP5031, P < .01) and
also inhibited TCM-induced BEC tube formation (32.2% inhibition
with 10 μM SP5031; 58.0% inhibition with 50 μM SP5031, P < .05;
Figure 1, F and G ).
SP5031 Exhibits Antilymphangiogenic and Antiangiogenic
Activity in MDA-MB-231 Tumor Xenografts
We next tested the activity of SP5031 in an MDA-MB-231 ortho-
topic xenograft model. We showed that 15 mg/kg SP5031 adminis-
tered i.p. daily delayed tumor growth compared to a PBS-treated
control group. At the end of the experiment, the SP5031-treated
group showed 51.0% less tumor growth than the control group (P <
.05; Figure 2A). Immunostaining with mouse anti-CD34 and mouse
anti–LYVE-1 demonstrated that SP5031 blocked formation of stromal
blood and LVs in both intratumoral and peritumoral areas (Figure 2D).
There were 35.7% fewer blood vessels and 62.0% fewer LVs (P < .05) in
tumor tissues from animals treated with SP5031 (Figure 2, B and C ).
SP5031 Blocks Migration of MDA-MB-231 and MCF-7
Breast Cancer Cells
We performed tumor cell migration assay using Platypus cell migra-
tion kits (Figure W7). Tumor cell migration is one of the standards to
determine tumorigenic potential of the cancer cells. We treated MDA-
MB-231 cells with SP5031 because we have observed that SP5031
delayedMDA-MB-231 tumor growth in vivo. We additionally assessed
SP5031 on MCF-7 breast cancer cells, an estrogen receptor–positive
breast cancer cell line. Ten percent FBS induced significant migration
of MDA-MB-231 cells (P < .05); however, MCF-7 did not migrate at
that condition. At 25% FBS,MCF-7 showed significant migration (P <
.05); thus, we tested SP5031 at 25% FBS in both cell lines (FigureW7,
A and C ). We showed the inhibition of tumor cell motility on both
breast cancer cell types by treating with SP5031 (Figure W7, B and
D). SP5031 potently inhibited MDA-MB-231 cell migration at 60
and 20 μM (68% and 44% inhibition) and MCF-7 migration at 60,
20, and 6.7 μM (74%, 70%, and 65% inhibition, respectively).
SP5031 Blocks Adhesion of MCF-7 Breast Cancer Cells
We performed adhesion assays using MCF-7 breast cancer cells.
At 3 hours after cell seeding in 25% FBS, MCF-7 cells showed adhe-
sion on a fibronectin-coated plate. Peptide-treated group showed signif-
icant inhibition of cell adhesion compared to control (Figure W8).
SP5031 Shows Antilymphangiogenic and Antiangiogenic
Activity in Tumor-Conditioned Regional LNs
We developed a tumor-conditioned regional LN model by injecting
TCM subcutaneously into animals for 14 days to simulate the condi-
tioning of tumor-draining LNs by primary tumor–secreted factors that
are transported to the LNs through LVs [10,21]. We found that the
axillary and brachial LNs ofTCM-treated animals were two to three times
larger than those of SFM-treated animals. Next, we co-administered
SP5031 in TCM-treated animals. The SP5031-treated group showed
significant normalization of the LN volume (P < .05; Figure 3, A and
B). Anti-mouse LYVE-1 and anti-mouse MECA-79 antibodies were
used to detect LVs and high endothelial venules (LN-specific vascular
endothelium) in the LNs. TCM treatment enhanced LV density
Figure 2.MDA-MB-231 xenografts with SP5031 treatment. SP5031 blocks lymphangiogenesis and angiogenesis in MDA-MB-231 xeno-
grafts. (A) Changes in tumor volume of the PBS or SP5031-treated groups. After day 21, SP5031 significantly delayed tumor growth
compared to control (*P < .05). (B) Quantification of blood vessels in the tumors (*P < .05). (C) Quantification of LVs (*P < .05). (D)
Representative immunohistochemistry images from intratumoral and peritumoral regions of the tumor. Scale bars represent 100 μm.
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(LVD) by 87.7% in axillary LNs and by 66.0% in brachial LNs and
blood vessel density (BVD) by 101.0% in axillary LNs and by 98.2%
in brachial LNs. SP5031 normalized both TCM-enhanced LVD and
BVD significantly (P < .05) (Figure 3, C and D). These results
demonstrate that SP5031 blocks both LN lymphangiogenesis and
LN angiogenesis in tumor-conditioned axillary and brachial LNs.
SP5031 Blocks TCM-Induced VEGFR2 Phosphorylation
The pro-angiogenic and pro-lymphangiogenic factors present in
TCM were determined using Proteome Profiler Human Angiogenesis
Array Kits. MDA-MB-231 cells expressed pro-angiogenic factors,
including angiogenin, chemokine ligand 16, heparin-binding epi-
dermal growth factor–like growth factor, matrix metalloproteinases
8 and 9, PDGF-AA, endothelin-1, interleukin 8, VEGFA, and pla-
cental growth factor. Interestingly, TCM contained antiangiogenic
factors as well, including serpin E1, serpin F1, tissue inhibitor of
metalloproteinase 1, and thrombospondin-1. However, a well-known
lymphangiogenic factor, VEGFC, was not detected in TCM (Fig-
ure 4A). Two million LECs pretreated with or without 50 μM SP5031
were stimulated by TCM. Lysates from these LECs were analyzed
Figure 3. Tumor-conditioned regional LN models with SP5031 treatment. SP5031 inhibits lymphangiogenesis and angiogenesis in
axillary and brachial LNs induced by TCM treatment. (A) Representative images of axillary and brachial LNs. Arrows represent macro-
scopically detectable blood vessels. Scale bars represent 3 mm. (B) LNs from TCM-treated mice show an increase in LN volumes.
SP5031 treatment normalized the volume of the LNs. *P < .05 and #P < .05 versus the TCM-treated group. (C) Representative immuno-
fluorescence images for LVs (green) and high endothelial venules [38]. Scale bars represent 100 μm. (D) Quantification of LVD and BVD in
LNs. TCM enhances LVD by 87.7% in axillary LN (ax-LN) and by 66.0% in brachial LN (br-LN) and BVD by 101.0% in ax-LN and by 98.2%
in br-LN. SP5031 treatment normalized the LVD and BVD in the LNs in TCM-treated animals significantly. *P< .05 (ax-LN), #P< .05 (br-LN)
in LVD and *P < .05 (ax-LN), #P < .05 (br-LN) in BVD.
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by p-RTK Proteome Array Kits to determine the phosphorylation
status of multiple RTKs. SP5031 specifically inhibited the phosphory-
lation of VEGFR2 by 87.0% compared to control; however, phosphory-
lation of VEGFR1 was not influenced by peptide treatment (Figure 4,
B and C ). Thus, the inhibition of VEGFR2 phosphorylation by
SP5031 must be a result of activity against the VEGFA that is present
in TCM (Figure 4A).
SP5031 Exhibits Antilymphangiogenic and Antiangiogenic
Activity in Matrigel Plug Assays
Next, we implanted Matrigel plugs containing VEGFA with or
without SP5031 into athymic nude mice (Figure 4D). We addition-
ally included bFGF and heparin in the Matrigel plugs, because bFGF
supports survival of endothelial cells and heparin enhances the inter-
action between VEGFA and VEGFR2. After 10 days, plugs contain-
ing VEGFA, bFGF, and heparin (positive control group) showed
pronounced angiogenesis that SP5031 significantly inhibited: CD34-
positive area was decreased by 74.0% compared to the growth factor-
treated control group (Figure 4, D and F). LYVE-1, a marker for LVs
was used to measure VEGFA-induced lymphangiogenesis in the plugs
[22]. SP5031 inhibited LVs by 65.4% compared to the control (Fig-
ure 4, E and G ). These results demonstrate that the antilymphangio-
genic and antiangiogenic activities of SP5031 are achieved by targeting
VEGFA in the plugs.
SP5031 Inhibits VEGFA/C-Dependent VEGFR2/3 Signals,
Resulting in Inhibition of Activation of Downstream Proteins
Given the result that SP5031 blocks the phosphorylation of
VEGFR2, we expanded our experiments to test for its effect on phos-
phorylation of VEGFR3 on LECs. VEGFR3, which is activated by
VEGFC, is one of the major receptors for lymphangiogenic signaling
on LECs.We tested SP5031 on LECs and BECs stimulated byVEGFC
and VEGFA separately (Figure 5). As shown in Figures 5A and W2,
SP5031 potently inhibited VEGFA-induced phosphorylation of
VEGFR2, focal adhesion kinase (FAK), MKK3/6, p38MAPK,
MAPKAPK2, and HSP27 in BECs (HUVECs and MECs). VEGFC-
dependent phosphorylation of VEGFR3, VEGFR2, and FAK in
LECs were also blocked by SP5031 (Figure 5B). This result was con-
firmed in a VEGFC-induced LEC migration assay in which 50 μM
SP5031 inhibited LEC migration by 80.0% (P < .05; Figures 5C and
W3). These results demonstrate that SP5031 inhibits the phosphory-
lation of VEGFR2, VEGFR3, and downstream proteins on LECs
and BECs.
NRP1/2 Are the Target Receptors of SP5031
We used a cross-linking strategy to identify potential receptors of
SP5031. SP5031 was conjugated to the trivalent Sulfo-SBED biotin-
carrying reagent (Figure W4A). The conjugated SP5031–Sulfo-SBED
(SP5031 probe) was applied to BECs or LECs followed by exposure to
Figure 4. TCM-induced p-RTK analysis and VEGFA-induced Matrigel plug assays. (A) Angiogenesis factors in MDA-MB-231 TCM. (B)
SP5031 (50 μM) inhibits phosphorylation of VEGFR2, not VEGFR1. (C) Percent p-RTK after treatment with SP5031, compared to control.
SP5031 treatment lowers the phosphorylation of VEGFR2. **P < .01 versus control. (D) Representative Matrigel plugs with VEGFA plus
or minus SP5031. Scale bars represent 10 mm. (E) Representative immunohistochemistry images from the Matrigel plugs. Images show
that SP5031 treatment blocks VEGFA-induced angiogenesis (CD34) and lymphangiogenesis (LYVE-1) in vivo. Scale bars represent 100 μm.
(F) Quantification of blood vessels in the plugs (*P < .05). (G) Quantification of LVs in the plugs (*P < .05).
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UV light to allow cross-linking to occur (Figure W4B). Given that
SP5031 inhibits VEGFR2 and VEGFR3 phosphorylation, we asked if
target proteins could be NRP1, NRP2, CD44, VEGFR2, or VEGFR3
in immunoblot analysis experiments using the corresponding anti-
bodies. NRP1 and NRP2 were suspected because of their role as co-
receptors of VEGFA and VEGFC in activation of VEGFR2 and
VEGFR3, respectively [23,24]. CD44 was also suspected because of
the role of CD44v3 and CD44v6 in endothelial cell migration and
Figure 5. Inhibition of VEGFC and VEGFA signaling by SP5031 binding to NRP2 and NRP1. (A) SP5031 blocks VEGFA-induced phos-
phorylation of VEGFR2 (Y1175) and p38MAPK signaling proteins, including MKK3/6 (S189, S207), p38MAPK (T180, Y182), MAPKAPK2
(T334), and HSP27 (S82). (B) VEGFC-dependent phosphorylation of VEGFR3 (p-Tyr), VEGFR2 (Y1175), and FAK (4G10) were inhibited by
SP5031 in LECs. GAPDH levels were used to control for the amount of total proteins in all cases. (C) VEGFC-induced LEC migration with
or without SP5031 (*P < .05). (D) We identified target receptors of SP5031 by using a cross-linking strategy. Biotinylated (cross-linked)
proteins are purified and probed using antibodies: The biotinylated target proteinswere found to beNRP1 (80, 120 kDa) and NRP2 (130 kDa).
(E) Co-IP assays were performed to optimize complex formation between VEGFR2 and NRP1 in the presence of VEGFA. (F) Treatment with
SP5031 hindered VEGFA-induced complex formation between NRP1 and VEGFR2 in HUVECs. (G) Treatment with SP5031 blocked VEGFC-
induced complex formation between NRP2 and VEGFR3 in LECs.
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adhesion through VEGFR2 signaling in the presence of VEGFA
[25,26]. Surprisingly, we found that NRP1 and NRP2 but not
CD44 and VEGFR2/3 cross-linked to SP5031 on LECs and BECs
(Figure 5D). Next, we performed co-IP experiments with VEGFR2/
3 and NRP1/2 antibodies in the presence of VEGFA/C with or with-
out SP5031, as described previously [23]. We showed that upon acti-
vation with VEGFA, VEGFR2 and NRP1 formed a receptor complex
(Figure 5E ). SP5031 treatment hindered VEGFA-induced VEGFR2/
NRP1 complex formation in BECs, and VEGFC-induced VEGFR3
and NRP2 complex formation in LECs (Figure 5, F andG ). However,
VEGFR2 and CD44 complex formation in BECs was not inhibited by
SP5031 treatment consistent with the finding that CD44 is not a target
receptor of SP5031 (Figure W5). These results demonstrate that the
peptide binding to NRP1/2 hinders receptor complex formation
between VEGFR2/3 and NRP1/2, which results in suppression of
VEGFA/C signal transduction.
Figure 6. SP5031 binding to its receptors is specific. (A) Alanine scan of SP5001 to eliminate proliferation inhibitory activity of SP5001.
(B) Flowchart for the identification of control peptides. (C) Peptide sequence comparison between SP5031 and SP5002. (D) SP5031
probe bound to NRP1 and NRP2 on BECs and LECs (lane 1). Competition with 10× unlabeled SP5031 lowered the amount of binding
of SP5031 probe to its target receptors (lane 2). SP5002 probe did not bind to the same target receptors (lane 3). Competition with 10×
unlabeled SP5002 did not hinder the binding of SP5031 probe to its target receptors (lane 4). (E) Percent LEC migration. SP5002 did not
cause inhibition of LEC migration. However, SP5031 showed potent inhibition (*P< .05 and **P < .01). (F) Percent BEC migration (*P <
.05). (G) VEGFC-induced phosphorylation of VEGFR3 was not significantly inhibited by SP5002 compared to SP5031. (H) VEGFA-induced
phosphorylation of VEGFR2 was not inhibited by SP5002. (I) VEGFC-dependent complex formation between VEGFR3 and NRP2 was
significantly dissociated by SP5031, however, not by SP5002.
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SP5002, a Peptide Homologous to SP5031, Is Inactive
We generated a sham peptide, SP5002, which is homologous to
wild-type SP5031 (Figure 6). In a previous screen of a number of
somatotropin peptides on cell proliferation, migration, and adhesion
of LECs, MECs, and HUVECs, we discovered that SP5001 (amino
acid sequence: RLRLLTLQSWLL-NH2) had antiproliferative but
no antimigratory activity (Figure 6B) [19]. We performed an alanine
scan of SP5001 to determine the amino acids that are crucial for its
antiproliferative activity. We discovered that SP5002, SP5003,
SP5005, SP5006, and SP5011 did not inhibit LEC proliferation
(Figure 6A). Among them, SP5002 has a nearly identical isoelectric
point (of 9.75) to SP5031 (Figure 6C ), suggesting that the overall
surface charge and peptide solubility of SP5002 are comparable to
those of SP5031 under the same experimental conditions. First,
the effect of SP5002 and SP5031 on TCM-induced migration of
LECs and BECs was evaluated. Even at 50 μM, SP5002 did not
significantly inhibit migration of either cell type. SP5031 potently
inhibited migration of both cell types under the same conditions
Figure 7.Mechanisms of action of SP5031. SP5031 inhibits lymphangiogenesis and angiogenesis in primary tumors and tumor-conditioned
regional LNs. This suggests the potential of SP5031 to prevent both tumor growth and tumor metastasis (upper panel, hypothetical
mechanisms are shown in a red dotted rectangle). At the cellular level, SP5031 targets LECs and BECs (lower panel). NRP1 (on BECs)
and NRP2 (on LECs) are the target receptors. Peptide binding to NRP1 and NRP2 indirectly inhibits signaling from VEGFR2 and VEGFR3
in the presence of VEGFA and VEGFC. SP5031 further inhibits VEGF-induced phosphorylation of p38MAPK signaling molecules and FAK,
element proteins for endothelial cell migration and adhesion.
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(Figure 6, E and F ). Next, SP5002 did not significantly inhibit
VEGFA-induced phosphorylation of VEGFR2 on BECs and
VEGFC-induced phosphorylation of VEGFR3 on LECs (Figure 6,
G and H ). SP5002 also did not hinder VEGFC-induced complex
formation between VEGFR3 and NRP2 unlike SP5031 (Figure 6I ).
A cross-linking experiment in the presence of excess peptide as a com-
petitor was performed with the SP5002 probe and the SP5031 probe
(Figure 6D). SP5031 probe was efficiently cross-linked to NRP1 (120,
80 kDa) andNRP2 (130 kDa) on BECs and LECs (Figure 6D, lane 1).
When unconjugated SP5031 at a 10-fold excess to SP5031 probe was
included in the cross-linking assay, cross-linking of SP5031 probe to
the target receptors was significantly reduced (Figure 6D, lane 2). These
results demonstrate specific binding of SP5031 to these target recep-
tors. SP5002 probe showed no binding to NRP1 and NRP2 in BECs
and LECs (Figure 6D, lane 3). Very importantly in a competition assay,
a 10-fold excess of SP5002 was not able to compete for binding to
receptors of SP5031 (Figure 6D, lane 4). These results demonstrate that
the activity of SP5031 is not because of nonspecific binding due to its
overall surface charge but because of sequence specific interactions with
the target receptors.
Discussion
Most malignant tumors exploit adaptive-evasive responses to the
VEGF monoclonal antibody (bevacizumab) by switching their
dependence to alternative pro-angiogenic signals and enhancement
of distant metastasis mediated by lymphatics [13,16]. Sunitinib, a
multitargeted tyrosine kinase inhibitor, however, exhibited anti-
angiogenic activity and allowed less lymphatic metastasis, as it targets
both angiogenesis and lymphangiogenesis by inhibiting a large number
of RTKs, including the VEGFRs and PDGF receptors [27]. In addi-
tion to those receptors, sunitinib blocks more than 70 tyrosine kinases
with other activities, which are thought to lead to several side effects
(e.g., hand-foot syndrome, stomatitis, hypothyroidism, and derma-
tologic toxicities) [28]. The two different examples discussed above
(bevacizumab and sunitinib) suggest that single-target drugs are
inadequate as therapeutics and also that agents that inhibit multiple
common targets such as tyrosine kinases or G protein-coupled re-
ceptors (GPCRs) are problematic as effective therapeutics because
of toxicity. However, we expect SP5031 to be an effective cancer
therapeutic because it inhibits angiogenesis and lymphangiogenesis,
two of the primary drivers of tumor growth and metastasis, highly
specifically, thus we expect with minimal toxicity.
In terms of cytotoxicity of SP5031, we previously evaluated apop-
totic and cytotoxic activities of SP5031, using caspase-3/7 and lactate
dehydrogenase tests [19]. In this study, we showed no cytotoxicity or
apoptosis at 1, 10, and 100 μM SP5031 in HUVECs, MECs, and
LECs. After treating with SP5031 for 27 days, we collected mouse
organs, including lungs, liver, spleen, and kidney for H&E staining
(Figure W6). We did not observe any significant changes within
SP5031-treated groups and vehicle (PBS)–treated group. We hypothe-
size that SP5031 that is primarily blocking cell migration and adhesion,
but not proliferation, may have advantage over cell death–inducing
conventional chemotherapeutics (Figure W7 and W8).
In this study, SP5031 selectively suppressed VEGFC/VEGFA-
induced VEGFR3/VEGFR2 signaling pathways by targeting NRP2
and NRP1 on LECs and BECs. VEGFC-dependent VEGFR3 acti-
vation is a major pro-lymphangiogenic signal in LECs [22]. In addition,
VEGFR2 is a validated target for VEGFA-dependent angiogenesis and
lymphangiogenesis [22]. Thus, SP5031 has the potential to simul-
taneously inhibit lymphangiogenesis and angiogenesis. Recent studies
with combination therapies, blocking both lymphangiogenesis and
angiogenesis, have shown better outcomes in several experimental
models. Targeting cyclooxygenase-2 (COX-2) and prostaglandin E
receptors decreased angiogenesis and lymphangiogenesis, improving
overall survival rates in breast tumor xenograft models [29]. A combina-
tion therapy with short interfering RNA (siRNA) against VEGFC and
VEGFA suppressed lymphogenous as well as hematogenous metastasis
in mammary tumor models [30]. Bevacizumab combined with a ge-
netic blockade of insulin-like growth factor 1 reduced angiogenesis and
lymphangiogenesis in gastric cancer models [31]. Accordingly, multi-
targeted antilymphangiogenic and antiangiogenic agents have a potential
to generate better therapeutics to efficiently inhibit tumor progression
and metastasis. To our knowledge, this is the first study targeting
tumor-induced lymphangiogenesis and angiogenesis with one short pep-
tide. Previous studies used a combination of two (or more) antibodies,
genetic modifications, large proteins, and short interfering RNA [29–
31]. The peptide needs to be further modified with sequence mutations
for an improved in vivo stability, as we discussed previously [32].
SP5031 activity in vivo was assessed in a breast tumor xenograft
study. SP5031 slowed down tumor growth and blocked lymphangio-
genesis and angiogenesis in peritumoral and intratumoral areas of
primary tumors in MDA-MB-231 xenograft models (Figure 2). These
results suggest that SP5031 could inhibit tumor cell dissemination
through stromal LVs and blood vessels in addition to delaying primary
tumor growth facilitated by blood vessels (Figure 7, upper panel ). We
further evaluated the in vivo activity of SP5031 in tumor-conditioned
regional LNs (Figure 3). In this LN model, we observed two to three
times larger, more pro-angiogenic, and pro-lymphangiogenic axillary
and brachial LNs in TCM-treated animals. SP5031 treatment inhib-
ited the increase in the LN volume and the LVDs and BVDs in the
LNs. As shown in Figure 7 (upper panel), we can speculate that the
inhibition of LN lymphangiogenesis by SP5031 could delay tumor
invasion into the LNs by limiting lymphatic flow [21]. At the same
time, the inhibition of LN angiogenesis by SP5031 could block the
conditioning of metastatic niches in the LNs, thus depriving tumor
cells that may have metastasized to the LNs of sufficient oxygen and
nutrients [33].
In the proposed mechanism of action of SP5031 (Figure 7, lower
panel ), SP5031 blocks the activities of VEGFR2/3 by binding to
NRP1/2. Recently, we have shown that VEGFR2 is expressed on
both BECs and LECs, and blockade of VEGFR2 by SP5031 showed
dual inhibition of LECs and BECs [34]. With the present data that
SP5031 blocks VEGFR3 that is expressed exclusively predominantly
on LECs, SP5031 mostly targets VEGFR2 through the binding to
NRP1 and partially blocks VEGFR3 through NRP2. NRP1 and
NRP2 have three common structural motifs: two CUB homology
domains, two coagulation factor V/VIII homology domains, and a
MAM domain. In addition to having similar motifs, NRP1 and
NRP2 share 44% amino acid sequence identity [35]. Peptide bind-
ing to NRP1 and NRP2 blocks complex formation between
VEGFR2 and NRP1 (on BECs) and VEGFR3 and NRP2 (on
LECs), indirectly inhibiting signaling from VEGFR2 and VEGFR3
in the presence of VEGFA and VEGFC. NRP1/2-mediated inhibi-
tion of VEGFR2/3 suggests that SP5031 may synergize with the
currently used VEGFA monoclonal antibody (bevacizumab) and
the VEGFR2 monoclonal antibody, ramucirumab [36]. At the intra-
cellular level (Figure 7, lower panel ), SP5031 inhibits FAK and
p38MAPK-related proteins. It is known that p38MAPK and HSP27
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activate actin reorganization, inducing endothelial cell migration [37].
FAK is central for focal adhesion turnover that is required for endo-
thelial cell adhesion and migration. Thus, the antimigratory and anti-
adhesive activities of SP5031 can be explained by its inhibition of
FAK and p38MAPK.
Taken together, these findings show that SP5031 is capable of
directly tuning lymphangiogenesis and angiogenesis through multi-
modal inhibitory mechanisms to improve current antiangiogenic strat-
egies in cancer treatment.
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Figure W1. Real-time analysis of LEC/BEC migration and adhesion. SP5031 was tested in TCM-induced LEC/BEC migration and adhe-
sion, using RTCA System combined with CIM-plate and E-plate. Cell indices are proportional to the number of migrated or adhesive
LECs/BECs (A) Real-time LECmigration in TCMwith our without SP5031 (CIM-plate). (B) BECmigration. (C) Real-time LEC adhesion (E-plate).
(D) BEC adhesion.
Figure W3. VEGFC-induced LECmigration. LECmigration wasmea-
sured in real-time with or without SP5031 treatment. SP5031 inhib-
ited VEGFC-dependent LEC migration.
Figure W2. VEGFAsignalingwithSP5031 treatment inMEC.HUVECs
are routinely used in endothelial cellWestern blot assays (in Figure 5A)
but, because of their venous origin, may not adequately reflect micro-
capillaries of tumors. As an additional study, we look at the effect of
SP5031 inMECs.VEGFA-inducedphosphorylationof VEGFR2 (Y1175)
and FAK (4G10) was blocked by SP5031 inMECs. GAPDHwas mea-
sured as a loading control.
Figure W4. Sulfo-SBED cross-linking methodology. (A) A Sulfo-SBED Biotin Label Transfer Reagent (Thermo Scientific Inc) has three
functional groups, including an amine-reactive NHS-ester group, a UV-activatable aryl azide group, and a biotin group. The peptide was
reacted with Sulfo-SBED in PBS at room temperature for 2 hours, in the dark. (B) Probe-conjugated peptide was added to HUVECs or
LECs in PBS in a 24-well plate and the plate was exposed in UV (365 nm) for 15 minutes. Then, the biotin groups are reacted with target
receptors, making chemical bonds: The biotinylated target receptors were purified by using anti-biotin and then probed by target
receptor antibodies.
Figure W5. VEGFR2/CD44 or VEGR2/NRP1 complex formation
with SP5031 treatment. VEGFA induces VEGFR2 and CD44 com-
plex formation as well as VEGFR2 and NRP1 complex in HUVECs.
SP5031 binds to NRP1 and dissociates the VEGFR2 and NRP1
complex formation. However, SP5031 does not inhibit VEGFR2 and
CD44 complex formation, as SP5031 has no interaction with CD44.
Figure W6. SP5031 is not toxic to normal tissues as seen by histopathology. Histopathological examination of liver, lung, spleen, and
kidney was performed by H&E staining. No significant morphologic changes were seen in these organs from animals treated with
SP5031, compared to the organs from the control group of animals. Scale bars represent 500 μm.
Figure W7. SP5031 inhibits migration of both MDA-MB-231 and MCF-7 cells. The effect of SP5031 on cancer cell migration on fibronectin-
coated Platypus migration plates was tested. (A) Optimization of the experimental condition. MCF-7 is relatively passive in migration, com-
pared to MDA-MB-231 cells; thus, we could not see a significant MCF-7 migratory induction in 10% FBS. Twenty-five percent FBS was
determined to adequately induce migration of both cell lines. Scale bars represent 500 μm. (B) SP5031 inhibited migration (at 18 hours) of
MDA-MB-231 and MCF-7 cells. Scale bars represent 500 μm. (C) Quantification of A by measuring fluorescence. *P < .05 and **P < .01
versus serum-free condition. NS represents “not significant.” (D) Quantification of B. SP5031 potently inhibited migration of both cells from
both types of breast cancer. *P < .05 and **P < .01 versus 25% FBS induction. Fluorescent intensity of the migrated MDA-MB-231 cells
(25% FBS) was set at 1.0.
Figure W8. SP5031 inhibits adhesion of MCF-7 cells. The effect of SP5031 on MCF-7 cell adhesion on fibronectin-coated well plates was
tested. (A) CellTracker Green–labeled MCF-7 cells adhered within 3 hours in 25% FBS. SP5031 treatment potently blocked the adhesion.
(B) Quantification of A. *P < .05 versus 25% FBS induction without the peptide.
